Discover
NAMS
NewAmsterdam Pharma Company N.V.
21.57
2 x 19.66
2 x 33.17
bid
ask
+
0.31
1.48%
2 @ 07:16 PM
21.56 -0.02 (0.07%)
| Ytd | -38.50% | |
| 1y | -34.64% |
21.02
day range
21.79
21.16
52 week range
41.45
| Open | 21.26 | Prev Close | 21.26 | Low | 21.02 | High | 21.79 | Mkt Cap | 2.52B |
| Vol | 1.27M | Avg Vol | 1.36M | EPS | -2.16 | P/E | N/A | Forward P/E | -14.13 |
| Beta | 0.10 | Short Ratio | 11.99 | Inst. Own | 106.58% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 25.10 | 200-d Avg | 30.92 | 1yr Est | 49.63 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-04 | 2026-09 | -0.5 | N/A | N/A | N/A |
| 2026-08-05 | 2026-06 | -0.48 | -0.52 | -0.04 | -7.90% |
| 2026-05-07 | 2026-03 | -0.46 | -0.4 | 0.06 | 13.04% |
| 2026-02-18 | 2025-12 | -0.43 | -0.63 | -0.2 | -45.09% |
| 2025-11-05 | 2025-09 | -0.38 | -0.61 | -0.23 | -60.53% |
| 2025-08-06 | 2025-06 | -0.52 | -0.15 | 0.37 | 71.15% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-10-05 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-09-08 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-08-06 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-06-30 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-02-19 | Guggenheim | Upgrade | Buy | Buy |
| 2026-02-18 | Needham | Upgrade | Buy | Buy |
Profile
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-01-06 | AUDET JULIETTE BERANGERE | Officer | 15.10K | Stock Award(Grant) |
| 2026-09-13 | DAVIDSON MICHAEL H | Chief Executive Officer | 1.08M | Purchase |
| 2024-12-29 | FORGROWTH NAP B.V. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2025-01-06 | JONES WILLIAM A JR | Officer | 43.00K | Stock Award(Grant) |
| 2026-08-23 | KASTELEIN JOHANNES JACOB PIETER | Officer and Director | 0.00 | Sale |
| 2025-07-15 | KLING DOUGLAS F | Chief Operating Officer | 44.00K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Frazier Life Sciences Management, L.P. | 18.09M | 390.27M | 15.13% |
| 2026-06-29 | Capital World Investors | 12.23M | 263.87M | 10.23% |
| 2026-06-29 | FMR, LLC | 10.34M | 223.08M | 8.65% |
| 2026-06-29 | RA Capital Management, L.P. | 9.55M | 206.05M | 7.99% |
| 2026-06-29 | FCPM III Services B.V. | 8.49M | 183.18M | 7.10% |
| 2026-06-29 | Deerfield Management Company, L.P | 4.26M | 92.01M | 3.57% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | SmallCap World Fund Inc | 9.27M | 199.92M | 7.75% |
| 2026-08-30 | Fidelity Contrafund | 2.33M | 50.19M | 1.95% |
| 2026-08-30 | Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 2.29M | 49.39M | 1.92% |
| 2026-08-30 | Fidelity Select Portfolios-Select Health Care Portfolio | 980.00K | 21.14M | 0.82% |
| 2026-06-29 | New Economy Fund | 957.48K | 20.66M | 0.80% |
| 2026-06-29 | T. Rowe Price Health Sciences Fund, Inc. | 912.50K | 19.69M | 0.76% |